Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0U4TN
|
|||
| Former ID |
DNC007986
|
|||
| Drug Name |
2-(2-hexylphenyl)isoindoline-1,3-dione
|
|||
| Synonyms |
CHEMBL245943; PP60; BDBM23841
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Discovery agent [ICD-11: N.A.] | Investigative | [1] | |
| Structure |
 |
Download2D MOL |
||
| Formula |
C20H21NO2
|
|||
| Canonical SMILES |
CCCCCCC1=CC=CC=C1N2C(=O)C3=CC=CC=C3C2=O
|
|||
| InChI |
1S/C20H21NO2/c1-2-3-4-5-10-15-11-6-9-14-18(15)21-19(22)16-12-7-8-13-17(16)20(21)23/h6-9,11-14H,2-5,10H2,1H3
|
|||
| InChIKey |
USXHUJLIZBGCGH-UHFFFAOYSA-N
|
|||
| PubChem Compound ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Oxysterols receptor LXR-alpha (NR1H3) | Target Info | Inhibitor | [1] |
| KEGG Pathway | PPAR signaling pathway | |||
| Non-alcoholic fatty liver disease (NAFLD) | ||||
| Hepatitis C | ||||
| Pathway Interaction Database | RXR and RAR heterodimerization with other nuclear receptor | |||
| WikiPathways | Nuclear Receptors in Lipid Metabolism and Toxicity | |||
| Nuclear Receptors Meta-Pathway | ||||
| PPAR Alpha Pathway | ||||
| Liver X Receptor Pathway | ||||
| Adipogenesis | ||||
| SREBF and miR33 in cholesterol and lipid homeostasis | ||||
| Nuclear Receptors | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Co-existence of alpha-glucosidase-inhibitory and liver X receptor-regulatory activities and their separation by structural development. Bioorg Med Chem. 2008 Apr 15;16(8):4272-85. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.